Literature DB >> 15028438

Costs of urinary incontinence and overactive bladder in the United States: a comparative study.

Teh-Wei Hu1, Todd H Wagner, Judith D Bentkover, Kristi Leblanc, Steve Z Zhou, Timothy Hunt.   

Abstract

OBJECTIVES: To update the cost of urinary incontinence (UI) for year 2000 and compare it with the cost of overactive bladder (OAB).
METHODS: Using the cost-of-illness framework, disease epidemiologic data were combined with treatment rates, consequence probabilities, and average cost estimates. All costs reflect the costs during 2000.
RESULTS: The total cost of UI and OAB was 19.5 billion dollars and 12.6 billion dollars, respectively (year 2000 dollars). With UI, 14.2 billion dollars was borne by community residents and 5.3 billion dollars by institutional residents. With OAB, 9.1 and 3.5 billion dollars, respectively, was incurred by community and institutional residents.
CONCLUSIONS: OAB affected 34 million individuals compared with 17 million with UI. Despite the differences in epidemiology, the total and per-person costs of UI were higher than the OAB costs because OAB individuals without incontinent episodes incurred fewer costs, on average.

Entities:  

Mesh:

Year:  2004        PMID: 15028438     DOI: 10.1016/j.urology.2003.10.037

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  90 in total

1.  The Impact of Obesity and Weight Loss on Urinary and Bowel Incontinence Symptoms in Women.

Authors:  Alicia C Ballard; Holly E Richter
Journal:  Menopausal Med       Date:  2011-08-01

Review 2.  Pharmacological management of women with mixed urinary incontinence.

Authors:  Hashim Hashim; Paul Abrams
Journal:  Drugs       Date:  2006       Impact factor: 9.546

3.  Effects of birth trauma and estrogen on urethral elastic fibers and elastin expression.

Authors:  Guiting Lin; Hongxiu Ning; Guifang Wang; Lia Banie; Tom F Lue; Ching-Shwun Lin
Journal:  Urology       Date:  2010-05-15       Impact factor: 2.649

Review 4.  Slings in surgery of genuine stress incontinence.

Authors:  Silvia Secco; Alessandro Crestani; Francesco Cattaneo; Vincenzo Ficarra; Filiberto Zattoni; Giacomo Novara
Journal:  World J Urol       Date:  2011-10-15       Impact factor: 4.226

5.  Economic evaluation of sacral neuromodulation in overactive bladder: A Canadian perspective.

Authors:  Magdy M Hassouna; Hamid Sadri
Journal:  Can Urol Assoc J       Date:  2015 Jul-Aug       Impact factor: 1.862

Review 6.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

7.  Tegresstrade mark Urethral Implant Phase III Clinical Experience and Product Uniqueness.

Authors:  Roger R Dmochowski
Journal:  Rev Urol       Date:  2005

8.  Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin.

Authors:  Linda Cardozo; David Castro-Diaz; Marc Gittelman; Arwin Ridder; Moses Huang
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2006-04-20

9.  Pelvic floor consequences of cesarean delivery on maternal request in women with a single birth: a cost-effectiveness analysis.

Authors:  Xiao Xu; Julie S Ivy; Divya A Patel; Sejal N Patel; Dean G Smith; Scott B Ransom; Dee Fenner; John O L Delancey
Journal:  J Womens Health (Larchmt)       Date:  2010-01       Impact factor: 2.681

Review 10.  Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations.

Authors:  Hashim Hashim; Paul Abrams
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.